Accountable Care Organizations: What Impact on Pharma?
|出版日期||內容資訊||英文 50 Pages
|ACO:對製藥公司帶來的影響 Accountable Care Organizations: What Impact on Pharma?|
|出版日期: 2015年07月16日||內容資訊: 英文 50 Pages||
ACO (Accountable Care Organization:對患者具有責任的治療組織) 是美國新醫療保健系統實體。
The Affordable Care Act (ACA) passed in 2010 was the catalyst to a range of changes to the US healthcare system. Among the most important of these changes was how healthcare is paid for, with a number of ACA measures aimed at moving away from a fee-for-service reimbursement to payment of providers according to outcomes and quality of care. This shift from volume- to value-based reimbursement is captured most prominently in the establishment of Accountable Care Organizations (ACOs). ACOs are groups of doctors, hospitals, and other healthcare providers that share the risk, responsibility, and reward associated with delivering more cost-effective, higher-quality, and better-coordinated care. There are now over 700 ACOs in the US, spanning both the publicly funded Medicare and Medicaid, as well as the private sector.
The impact of this growing ACO movement on the pharma industry has so far been limited, but this is changing. Pharma firms have opportunities to engage with these restructured providers in new ways, including by helping to influence and set treatment best practice across different therapy areas, providing pharmacoeconomic and outcomes data, and potentially supporting a more prominent role for pharmacists within ACOs.
This report addresses the following questions: